Currently, AZD3965, which is an orally administrable second-generation MCT1/MCT2 inhibitor, is being investigated in a Phase I clinical trial for the treatment of advanced solid tumors, particularly prostate cancer, gastric cancer, and diffuse large B cell lymphoma [23]. Here, SLC16A1 is linked to gastric cancer.